Home Cancer Genetics and Molecular Tumor Testing DICER1 Genetic Test: Tumor Predisposition, Cancer Risk, and Results

DICER1 Genetic Test: Tumor Predisposition, Cancer Risk, and Results

By
Vita Library
-
3
Understand DICER1 genetic test results, pleuropulmonary blastoma and other tumor risks, mosaicism, childhood and adult surveillance, inheritance, and family testing.

A DICER1 genetic test looks for inherited or mosaic changes associated with a rare tumor predisposition syndrome that can affect the lungs, kidneys, thyroid, ovaries, eyes, brain, and other organs. The condition is especially important in childhood because pleuropulmonary blastoma can begin as a lung cyst and progress during the first years of life. Other characteristic findings include pediatric cystic nephroma, ovarian Sertoli-Leydig cell tumor, multinodular goiter, and differentiated thyroid cancer.

Most people with a germline DICER1 pathogenic variant do not develop every associated tumor, and many remain clinically unaffected. Risk is age dependent, varies by sex and variant mechanism, and is concentrated before age 40 for many manifestations. Testing may begin with a child or adult who has a characteristic tumor, multiple DICER1-related findings, or a known family variant. A positive result supports organ-specific surveillance beginning in infancy, testing of relatives, and expert pathology review when a suspicious tumor occurs. A tumor DICER1 mutation alone does not prove inherited syndrome because many sporadic tumors acquire two somatic DICER1 changes.

  • DICER1 predisposition is autosomal dominant with reduced, age-related penetrance.
  • Pleuropulmonary blastoma and lung cyst surveillance is most urgent in infancy and early childhood.
  • Ovarian, thyroid, kidney, eye, and selected brain manifestations require age-specific surveillance or symptom awareness.
  • A DICER1 change found only in tumor tissue must be confirmed in a germline sample before family risk is assigned.
  • Mosaic variants can be missed in blood and may require testing of more than one tissue.

Table of Contents

What DICER1 Does and How Tumors Develop

DICER1 encodes an endoribonuclease called Dicer. The protein cuts precursor microRNAs into mature microRNAs, which help regulate the expression of many other genes. Because microRNAs influence development, cell growth, and differentiation, disrupted Dicer activity can alter entire gene-regulatory networks.

Most inherited cases begin with a loss-of-function pathogenic variant in one copy of DICER1. The other copy remains functional in normal cells, which helps explain why many carriers are healthy. In a susceptible cell, an acquired second variant can affect specific “hotspot” amino acids in the RNase IIIb domain. This unusual two-hit combination changes microRNA processing and contributes to tumor formation.

The second hit is often not a complete loss of the remaining gene. It is typically a missense hotspot variant that selectively impairs processing of the 5p arm of precursor microRNAs. The resulting imbalance distinguishes DICER1-related tumor biology from a conventional tumor-suppressor mechanism in which both copies are simply deleted.

A germline DICER1 pathogenic variant is present in most cells and can be transmitted to children. A somatic variant is confined to a tumor or a subset of tissues and is not necessarily inherited. Many characteristic tumors can contain two somatic DICER1 variants in a person without germline predisposition. That is why tumor sequencing must be followed by constitutional testing before relatives are told they are at risk.

Mosaicism adds complexity. A pathogenic variant that occurred after fertilization may be present in only part of the body. Low-level mosaic loss-of-function variants can produce a phenotype similar to germline disease. Mosaic RNase IIIb hotspot variants may be associated with numerous disease foci and a more extensive presentation. Blood testing can be negative if the variant is absent or below detection in blood cells.

DICER1-related predisposition has reduced penetrance. Carrying a pathogenic variant does not mean a tumor is inevitable. Risk also changes with age: pleuropulmonary blastoma is predominantly a disease of infancy and early childhood, while thyroid and ovarian manifestations can appear later.

The condition is sometimes called DICER1 syndrome, DICER1-related tumor predisposition, or pleuropulmonary blastoma familial tumor predisposition syndrome. The broader term is preferred because lung tumors are only one part of the spectrum.

A pathogenic variant is distinct from a common polymorphism or a variant of uncertain significance, neither of which establishes the syndrome.

Tumors and Clinical Features Linked to DICER1

The most recognized manifestation is pleuropulmonary blastoma, or PPB, a rare childhood lung tumor. Type I PPB is cystic; type II has cystic and solid components; and type III is solid. Type Ir describes regressed or non-progressed cystic lesions. Type I can progress to the more aggressive type II or III form, making early recognition of lung cysts important.

PPB usually presents before age seven, with the greatest surveillance emphasis in infancy. Symptoms can include cough, rapid breathing, fever, chest pain, respiratory distress, or pneumothorax. A lung cyst in a child is not automatically PPB, but DICER1 status and expert radiologic review can change management.

Kidney manifestations include pediatric cystic nephroma, renal cysts, structural urinary anomalies, and rare anaplastic sarcoma of the kidney or Wilms tumor. Cystic nephroma often occurs in young children and can be the first clue to inherited predisposition.

Thyroid findings are common. Carriers have increased rates of multinodular goiter, thyroid nodules, and differentiated thyroid carcinoma, including papillary and follicular types. Most DICER1-associated thyroid cancers are well differentiated, although rare high-grade or poorly differentiated tumors occur. Thyroid nodules are much more common than thyroid cancer, so surveillance aims to avoid both delayed diagnosis and unnecessary surgery.

Ovarian sex cord-stromal tumors are another hallmark. Sertoli-Leydig cell tumors and gynandroblastomas may produce androgens, causing rapid-onset facial or body hair, deepening voice, acne, absent periods, or clitoral enlargement. Abdominal pain, distention, a pelvic mass, or precocious puberty can also occur. Most are diagnosed before age 40. Embryonal rhabdomyosarcoma of the cervix, uterus, or vagina and primary ovarian sarcoma are less common.

Ciliary body medulloepithelioma is a rare eye tumor that can cause reduced vision, leukocoria, eye pain, or glaucoma. Nasal chondromesenchymal hamartoma can produce persistent nasal obstruction, sinus symptoms, or facial swelling.

Rare central nervous system tumors include pituitary blastoma, pineoblastoma, DICER1-associated primary intracranial sarcoma, and selected embryonal tumors. Warning symptoms include persistent headache, vomiting, double vision, abnormal upward gaze, gait change, early puberty, or signs of Cushing syndrome.

Other reported features include macrocephaly, retinal abnormalities, liver cysts or multicystic liver lesions, intestinal polyps, dental anomalies, and rare sarcomas. The spectrum continues to evolve, and a highly unusual tumor may warrant expert molecular review.

No carrier is expected to develop all of these findings. Surveillance focuses on tumors with sufficient risk, an age window in which detection is useful, and a reasonable screening method.

Who Should Consider DICER1 Testing

Testing should be considered when a person has a tumor or pattern strongly associated with DICER1. A single characteristic childhood tumor can be sufficient, even without family history, because de novo and mosaic variants occur and relatives may be unaffected because penetrance is reduced.

Clinical indications include:

  • Pleuropulmonary blastoma of any type
  • Childhood lung cysts suspicious for type I or type Ir PPB
  • Sertoli-Leydig cell tumor or gynandroblastoma
  • Pediatric cystic nephroma
  • DICER1-associated renal sarcoma or selected Wilms tumors
  • Ciliary body medulloepithelioma
  • Nasal chondromesenchymal hamartoma
  • Pituitary blastoma, pineoblastoma, or primary intracranial sarcoma with DICER1 features
  • Embryonal rhabdomyosarcoma of the cervix or uterus
  • Multiple thyroid nodules or thyroid cancer at an unusually young age, especially with another DICER1 feature
  • More than one DICER1-spectrum tumor in one person or family
  • A DICER1 pathogenic variant detected in tumor tissue
  • A known familial germline DICER1 pathogenic variant

Pathology review matters because several DICER1-related tumors are rare and can resemble other entities. Central review by a specialist or registry can confirm the diagnosis and guide the most appropriate molecular testing. Tumor morphology may suggest DICER1 even before sequencing.

Testing is often performed on a multigene childhood cancer or hereditary tumor panel because the differential diagnosis includes other genes. For example, lung cysts and pneumothorax can occur in FLCN-related Birt-Hogg-Dubé syndrome; kidney tumors have several hereditary causes; and pineoblastoma can be associated with RB1 or genes in microRNA processing.

When tumor sequencing detects two DICER1 variants, one may be an inherited loss-of-function variant and the other a somatic hotspot, or both may be somatic. Germline testing should be offered with counseling. When possible, test an affected person first rather than an unaffected relative.

Unlike many adult-onset predisposition genes, predictive testing of children is appropriate because surveillance begins at birth. If a parent carries a known pathogenic variant, testing the newborn promptly allows lung and kidney screening to begin during the highest-risk period.

Pretest counseling should explain reduced penetrance, the possibility of mosaicism, the broad but rare tumor spectrum, radiation exposure from chest imaging, incidental findings, and implications for relatives. Families may need coordination among genetics, pediatrics, oncology, pulmonology, endocrinology, gynecology, radiology, ophthalmology, and surgery.

How the Test Is Performed

Germline testing usually begins with blood, saliva, or a buccal sample. The assay should include full DICER1 sequencing and deletion/duplication analysis. More than 90% of known pathogenic variants are detected by sequence analysis, while a smaller proportion are exon-level or whole-gene deletions or duplications.

Sequencing detects nonsense, frameshift, splice, and missense variants. Deletion/duplication analysis detects copy-number changes that sequencing may miss. A multigene panel should clearly state whether both methods were performed and whether mosaic variants below the standard allele-fraction threshold can be reported.

Tumor testing can identify the characteristic combination of a loss-of-function variant and an RNase IIIb hotspot. It may use DNA sequencing, RNA analysis, copy-number methods, or broader tumor profiling. Tumor results can support diagnosis but do not replace germline analysis.

When mosaicism is suspected, testing more than one tissue may be necessary. A negative blood result does not exclude a variant present in skin, saliva, urine-derived cells, tumor, or another tissue. The best samples depend on the clinical pattern and which embryologic lineages may carry the variant. A genetics laboratory should design the strategy because contamination by blood cells can complicate saliva and buccal testing.

High-depth sequencing or digital PCR can detect low-level mosaic variants. If a tumor contains a candidate constitutional variant, the laboratory may test several unaffected tissues with a method optimized for that exact change. Cultured skin fibroblasts can provide a non-blood source, although culture adds time.

The report should include the exact HGVS DNA and protein notation, transcript, zygosity or estimated mosaic fraction, classification, detection method, and limitations. It should distinguish a germline loss-of-function pathogenic variant from a tumor hotspot mutation because their implications differ.

A targeted familial-variant test is appropriate for relatives once the family’s pathogenic variant is known. Broad panel testing in every relative is unnecessary unless their personal history suggests an additional syndrome.

A prenatal or newborn sample requires careful chain of custody and laboratory expertise. If prenatal testing is chosen, chorionic villus sampling or amniocentesis can test for the known familial variant. Because surveillance starts in infancy and the phenotype is variable, counseling should address what a positive result can and cannot predict.

How to Read Positive, Negative, and VUS Results

A positive germline result identifies a pathogenic or likely pathogenic DICER1 variant in constitutional DNA. It establishes DICER1-related tumor predisposition and supports surveillance for the carrier plus targeted testing for at-risk relatives. “Likely pathogenic” is generally managed the same as pathogenic.

The report may describe a heterozygous loss-of-function variant, such as a nonsense, frameshift, splice-site, or deletion change. These are the typical inherited variants. A germline RNase IIIb hotspot variant is unusual and may raise concern for mosaicism and a different phenotype. Expert review is appropriate.

A positive mosaic result means the variant is present in only a proportion of tested cells. The level in one tissue does not precisely predict the proportion in another tissue, tumor risk, or reproductive risk. Gonadal involvement may be possible even when blood levels are low, so transmission cannot be ruled out solely from allele fraction.

A negative result has different meanings. If a child tests negative for a known familial variant using an appropriate assay, the child generally does not need DICER1-specific surveillance for that variant. If no familial variant is known, a negative test does not exclude mosaicism, an undetected structural variant, another gene, or a misclassified tumor.

A negative blood test is less definitive when the person has multiple highly characteristic DICER1 tumors. Testing tumor tissue and additional normal tissues may be indicated. The laboratory should review read-level data for low-frequency variants and confirm that deletion/duplication analysis was included.

A variant of uncertain significance, or VUS, does not establish the syndrome. It should not be used for predictive testing in healthy relatives or as the sole reason for intensive surveillance. Clinical management may still be based on a highly characteristic tumor diagnosis, but the VUS itself is not actionable.

A tumor-only positive result requires classification of both variants and comparison with a normal sample. Two DICER1 variants in one tumor may be entirely somatic. A single hotspot variant without a loss-of-function change may reflect incomplete assay coverage or a different mechanism.

Benign and likely benign variants do not increase tumor risk. Variant classifications can change, so families should retain the report and remain connected with the genetics clinic or laboratory.

Results should be documented in a concise family letter that lists the exact variant, inheritance pattern, testing laboratory, and recommended age for testing relatives. This prevents relatives from ordering the wrong assay or relying on a tumor report alone.

Surveillance After a Positive Result

Surveillance is age specific because tumor risks change rapidly through childhood. It should be coordinated by a center familiar with DICER1 and adjusted for prior tumors, chemotherapy exposure, family history, symptoms, and updated guidance.

Current expert recommendations include frequent clinical assessment for relevant symptoms, often every six months or at routine visits. Families should know the signs of breathing difficulty, pneumothorax, abdominal or pelvic mass, hormone changes, thyroid enlargement, visual change, nasal obstruction, and neurologic symptoms.

Lung surveillance

Chest radiography is recommended every six months from birth through age eight, then annually through age 12. Low-dose chest CT is recommended at approximately three months and 30 months. A third-trimester prenatal ultrasound may be considered when a fetus is known to carry the variant. A person diagnosed after age 12 may have baseline chest imaging after individualized discussion.

CT is more sensitive for small lung cysts than radiography but exposes the child to ionizing radiation. Protocols should use pediatric low-dose technique, and images should be reviewed by radiologists familiar with PPB. Symptoms such as sudden chest pain or breathlessness require urgent evaluation regardless of the last normal scan.

Kidney surveillance

Abdominal ultrasound is recommended every six months through age eight, then annually through age 12. It evaluates the kidneys for cystic nephroma and other lesions without radiation. Some renal sarcomas have occurred after age 12, so extended or baseline imaging can be considered when diagnosis is later or history is concerning.

Thyroid surveillance

Clinical assessment looks for a neck mass, lymph nodes, hoarseness, swallowing difficulty, pain, or persistent cough. Current GeneReviews guidance describes thyroid ultrasound every three years beginning at age eight, with individualized alternatives because the benefit of very early detection is not established and benign nodules are common. Annual ultrasound for five years may be considered after chemotherapy because treatment can add thyroid risk.

Thyroid nodules are evaluated using age-appropriate ultrasound and biopsy criteria. A DICER1 variant does not mean every nodule requires surgery. Avoiding repeated unnecessary biopsies and total thyroidectomy is part of good surveillance.

Ovarian and gynecologic surveillance

For girls and women, pelvic ultrasound is recommended every six months from diagnosis until at least age 40, with shared decision-making after 40. Transabdominal ultrasound is appropriate in children; transvaginal ultrasound may be considered in older adolescents or adults when acceptable. Rapid virilization, irregular or absent periods, precocious puberty, pelvic pain, or distention warrants prompt evaluation even after a recent normal scan.

Eye and brain awareness

An annual eye examination can be considered from ages three through ten to look for ciliary body medulloepithelioma and visual abnormalities. Routine brain MRI for every asymptomatic child is not universally recommended. Urgent brain MRI is indicated for concerning neurologic or endocrine symptoms, and screening MRI in late adolescence or adulthood can be discussed individually.

Surveillance does not prevent every tumor and can produce false positives, anxiety, sedation needs, radiation exposure, and procedures. The schedule should be reviewed periodically rather than expanded indiscriminately.

Inheritance, Family Testing, and Reproductive Options

DICER1-related tumor predisposition is usually inherited in an autosomal dominant pattern. Each child of a person with a germline pathogenic variant has a 50% chance of inheriting it. Men and women can transmit the variant, and risk comes from either side of the family.

Many carriers have no tumors, so an apparently unaffected parent can still carry the familial variant. Parental testing helps determine whether the variant was inherited or arose de novo. If neither parent tests positive in blood, low-level parental mosaicism or gonadal mosaicism remains possible, and sibling risk is low but not always zero.

Because surveillance begins in infancy, testing at-risk children should occur soon after birth rather than waiting until adulthood. A child who tests negative for the familial variant can avoid repeated chest, kidney, thyroid, and pelvic imaging attributable solely to DICER1.

Cascade testing starts with first-degree relatives and extends through the side of the family where the variant is found. Testing should use the exact familial variant. A family member’s age and prior tumor history affect what baseline evaluations are needed after a positive result.

Mosaic carriers require individualized reproductive counseling. The variant fraction in blood cannot determine how many egg or sperm cells carry the change. A person with low-level mosaicism may still transmit a fully germline variant to a child.

Reproductive options include natural conception without testing, prenatal diagnosis, preimplantation genetic testing for monogenic disease, donor egg or sperm, adoption, or deciding not to have children. Because penetrance is reduced and severity cannot be predicted from the familial variant alone, families may weigh these options differently.

When a fetus is known to carry a pathogenic variant, prenatal ultrasound can look for lung cysts, although a normal scan does not exclude later disease. Delivery planning may involve maternal-fetal medicine, neonatology, pediatric surgery, and radiology if a large cystic lesion is present.

Family communication should emphasize that a positive result is a surveillance opportunity, not a prediction of inevitable cancer. Sharing the written report is crucial because the word “DICER1 mutation” without variant details may refer to a somatic tumor hotspot that has no inherited implication.

A familial variant test is the preferred test for relatives when the constitutional pathogenic variant has already been identified.

Limitations and Questions for the Care Team

Evidence for DICER1 surveillance comes from registries, observational cohorts, tumor natural history, and expert consensus because the syndrome is rare. Recommendations may change as more carriers are identified through population testing and as the benefits and harms of imaging become clearer.

Risk estimates can be biased toward severely affected families. A carrier identified because of an affected relative may have a different experience from a child diagnosed after PPB or a person found incidentally on a broad panel. The exact variant usually cannot predict which organ will be affected.

A negative blood result does not fully exclude mosaicism. Tumor-only results can be mistaken for germline findings. Thyroid and lung imaging can identify benign lesions that lead to additional procedures. These limitations make specialist interpretation important.

Useful questions include:

  • Was the DICER1 finding detected in germline tissue, tumor tissue, or both?
  • Is the variant loss-of-function, an RNase IIIb hotspot, mosaic, or a VUS?
  • Did testing include deletion/duplication analysis and sufficient depth for mosaicism?
  • Should another tissue be tested after a negative blood result?
  • Which surveillance schedule applies to the person’s current age and prior treatment?
  • Are chest CT scans using pediatric low-dose protocols?
  • How will thyroid nodules be managed without unnecessary surgery?
  • Which pelvic ultrasound method is appropriate for age and circumstances?
  • Does a tumor need central pathology or registry review?
  • Which relatives, including newborns, should have targeted testing now?
  • Should a molecular result be registered with an expert DICER1 or PPB program?
  • What symptoms require urgent imaging between scheduled visits?

Families should keep a portable surveillance summary showing completed and upcoming studies, radiation exposure, tumor history, pathology, and the exact variant. Care may span pediatric and adult systems, and transition planning prevents missed screening.

Seek urgent care for sudden breathing difficulty or chest pain, severe abdominal pain or swelling, acute vision change, a new neurologic deficit, persistent vomiting with headache, or rapidly developing virilization. These symptoms have many possible causes, but DICER1-related tumors can progress quickly and should be evaluated without waiting for the next surveillance appointment.

References

Disclaimer

This information is educational and does not replace individualized care from a clinical geneticist, genetic counselor, pediatric oncologist, radiologist, endocrinologist, gynecologist, or other DICER1 specialist. Surveillance schedules may change with age, prior tumors, treatment exposures, mosaicism, and updated expert guidance. Do not alter imaging or surgical plans solely from a genetic report without multidisciplinary review.

RELATED ARTICLESMORE FROM AUTHOR